APYX — Apyx Medical Cashflow Statement
0.000.00%
- $110.43m
- $115.74m
- $48.10m
- 39
- 24
- 98
- 54
Annual cashflow statement for Apyx Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -11.9 | -15.2 | -23.3 | -18.9 | -23.6 |
| Depreciation | |||||
| Non-Cash Items | 5.21 | 5.69 | 7.33 | 7.37 | 6.16 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -10.3 | -1.84 | -5.22 | 5.54 | -1.25 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -16.1 | -10.4 | -20.3 | -5.25 | -18 |
| Capital Expenditures | -0.581 | -0.723 | -1.01 | -0.533 | -0.722 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | — | — | 7.27 | 0 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.581 | -0.723 | -1.01 | 6.73 | -0.722 |
| Financing Cash Flow Items | 0.148 | 0.195 | 0 | 0.147 | 6.78 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.073 | 0.024 | 0.217 | 32.2 | 6.75 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -16.9 | -11 | -20.7 | 33.5 | -11.9 |